Vanguard Group’s Cue Biopharma CUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $919K | Sell |
100,468
-843
| -0.8% | -$15.5K | ﹤0.01% | 3795 |
|
|
2025
Q3 | $2.19M | Sell |
101,311
-4,934
| -5% | -$116K | ﹤0.01% | 3553 |
|
|
2025
Q2 | $2.17M | Buy |
106,245
+29,050
| +38% | +$620K | ﹤0.01% | 3510 |
|
|
2025
Q1 | $2.11M | Buy |
77,195
+8,656
| +13% | +$321K | ﹤0.01% | 3478 |
|
|
2024
Q4 | $2.24M | Buy |
68,539
+825
| +1% | +$31K | ﹤0.01% | 3533 |
|
|
2024
Q3 | $1.54M | Hold |
67,714
| – | – | ﹤0.01% | 3637 |
|
|
2024
Q2 | $2.52M | Sell |
67,714
-8,398
| -11% | -$415K | ﹤0.01% | 3486 |
|
|
2024
Q1 | $4.32M | Buy |
76,112
+5,015
| +7% | +$354K | ﹤0.01% | 3351 |
|
|
2023
Q4 | $5.63M | Buy |
71,097
+267
| +0.4% | +$19.1K | ﹤0.01% | 3238 |
|
|
2023
Q3 | $4.89M | Buy |
70,830
+2,546
| +4% | +$249K | ﹤0.01% | 3260 |
|
|
2023
Q2 | $7.48M | Buy |
68,284
+13,164
| +24% | +$1.55M | ﹤0.01% | 3113 |
|
|
2023
Q1 | $5.9M | Buy |
55,120
+4,156
| +8% | +$396K | ﹤0.01% | 3222 |
|
|
2022
Q4 | $4.36M | Buy |
50,964
+220
| +0.4% | +$20.1K | ﹤0.01% | 3370 |
|
|
2022
Q3 | $3.4M | Hold |
50,744
| – | – | ﹤0.01% | 3521 |
|
|
2022
Q2 | $3.79M | Sell |
50,744
-4,381
| -8% | -$512K | ﹤0.01% | 3519 |
|
|
2022
Q1 | $8.07M | Buy |
55,125
+3,415
| +7% | +$724K | ﹤0.01% | 3265 |
|
|
2021
Q4 | $17.5M | Sell |
51,710
-747
| -1% | -$289K | ﹤0.01% | 2917 |
|
|
2021
Q3 | $22.9M | Buy |
52,457
+533
| +1% | +$186K | ﹤0.01% | 2790 |
|
|
2021
Q2 | $18.1M | Buy |
51,924
+109
| +0.2% | +$42.2K | ﹤0.01% | 2901 |
|
|
2021
Q1 | $19M | Buy |
51,815
+3,664
| +8% | +$1.51M | ﹤0.01% | 2810 |
|
|
2020
Q4 | $18.1M | Buy |
48,151
+2,120
| +5% | +$847K | ﹤0.01% | 2689 |
|
|
2020
Q3 | $20.8M | Buy |
46,031
+1,442
| +3% | +$831K | ﹤0.01% | 2440 |
|
|
2020
Q2 | $32.8M | Buy |
44,589
+13,679
| +44% | +$9.9M | ﹤0.01% | 2202 |
|
|
2020
Q1 | $13.2M | Buy |
30,910
+1,253
| +4% | +$608K | ﹤0.01% | 2486 |
|
|
2019
Q4 | $14.1M | Buy |
29,657
+4,485
| +18% | +$1.41M | ﹤0.01% | 2691 |
|
|
2019
Q3 | $6.37M | Buy |
25,172
+4,767
| +23% | +$1.15M | ﹤0.01% | 3041 |
|
|
2019
Q2 | $5.5M | Buy |
20,405
+5,155
| +34% | +$1.28M | ﹤0.01% | 3131 |
|
|
2019
Q1 | $3.54M | Buy |
15,250
+5,441
| +55% | +$1.03M | ﹤0.01% | 3267 |
|
|
2018
Q4 | $1.38M | Sell |
9,809
-12,245
| -56% | -$2.22M | ﹤0.01% | 3471 |
|
|
2018
Q3 | $5.99M | Sell |
22,054
-224
| -1% | -$64.7K | ﹤0.01% | 3159 |
|
|
2018
Q2 | $7.93M | Buy |
22,278
+7,216
| +48% | +$2.87M | ﹤0.01% | 3016 |
|
|
2018
Q1 | $6.35M | Buy |
+15,062
| New | +$6.87M | ﹤0.01% | 3046 |
|
Other funds holding CUE
BL
LPC
Vanguard Group's CUE Position: Q4 2025 in Review
Vanguard Group reduced its Cue Biopharma (CUE) stake by 0.83% in Q4 2025, selling an estimated $15.5K and leaving 100,468 shares worth $919K. The position accounts for ﹤0.01% of the portfolio, ranked #3795.
Vanguard Group first reported a position in CUE in Q1 2018 and has held it in 32 quarters since. The position peaked at $32.8M in Q2 2020. 48 funds tracked by Wall St. Rank hold CUE as of Q4 2025.
- Vanguard Group held 100,468 shares of Cue Biopharma worth $919K as of Q4 2025.
- Vanguard Group sold 843 Cue Biopharma shares in Q4 2025, an estimated $15.5K.
- Cue Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3795 holding.
- Vanguard Group first reported a position in Cue Biopharma in Q1 2018 and has held it in 32 quarters since.
- Vanguard Group's Cue Biopharma position peaked at $32.8M in Q2 2020.
- 48 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.